8-K current report · filed Oct 19, 2026

ArriVent BioPharma, Inc. (AVBP) 8-K Current Report: October 19, 2026

Item EX-99.1Item 7.01AVBP overview

Short answer

ArriVent BioPharma, Inc. (AVBP) filed an 8-K current report with the SEC on October 19, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Publication of Phase 1b FURTHER trial results for firmonertinib in Cancer Cell.

ArriVent BioPharma, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Publication of Phase 1b FURTHER trial results for firmonertinib in Cancer Cell
  • Results concern FURMO-002, clinical trial NCT05364073
  • Peer-reviewed publication may support firmonertinib’s clinical credibility and investor assessment of development prospects

Item EX-99.1 · Exhibit EX-99.1

  • Cancer Cell publication strengthens firmonertinib’s clinical and mechanistic case in underserved EGFR PACC-mutant NSCLC
  • Front-line confirmed ORR reached 43% at 160 mg and 68% at 240 mg, with median PFS of 11.1 and 16.0 months
  • Intracranial ORR was 47% in patients with baseline brain metastases, including 41% complete responses
  • Phase 3 ALPACCA trial underway against investigator-choice osimertinib or afatinib, creating a key regulatory and valuation catalyst
  • ctDNA clearance by cycle 3 correlated with ORR of 70% versus 20% and median PFS of 15.1 versus 3.0 months

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ArriVent BioPharma, Inc. 8-K filings

Get the next AVBP 8-K as it lands

Follow AVBP for push alerts, or ask the research agent what this filing means.